MedTrace Logo

Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study

NCT00911521 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2011-10-12

No results posted yet for this study

Summary

The purpose of this trial is to study the effect of Human Papillomavirus (HPV) vaccination on the elevation of antibody titer to 4 serotypes of HPV in patients with systemic lupus erythematous and compare the antibody response with an equal number of age-matched healthy women.

Conditions

Interventions

DRUG

human papillomavirus vaccination (Gardasil)

3 doses of the human papillomavirus vaccines to be given at baseline, month 2 and month 6

Sponsors & Collaborators

  • Tuen Mun Hospital

    lead OTHER_GOV

Principal Investigators

  • Chi Chiu Mok, MD, FRCP · Tuen Mun Hospital, Hong Kong, China

Study Design

Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2011-03-31
Completion
2011-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00911521 on ClinicalTrials.gov